Liraglutide studies: 1,219 papers with results
Page 4 of 25
- The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: Results of a pilot randomized, double-blind, placebo-controlled trial.
Whicher CA · Diabetes, obesity & metabolism · 2021
Randomized controlled trial · 7 results
- Exploratory Analysis of Liraglutide Effects on Obstructive Sleep Apnea and Health-Related Quality of Life in Individuals With Obesity and COPD: A Secondary Analysis of a Randomised Controlled Trial.
Wolsing SK · Clinical obesity · 2026
Randomized controlled trial · 5 results
- Effects of Liraglutide Monotherapy on Beta Cell Function and Pancreatic Enzymes Compared with Metformin in Japanese Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Subpopulation Analysis of the KIND-LM Randomized Trial.
Tanaka K · Clinical drug investigation · 2015
Randomized controlled trial · 11 results
- Modulation of circulating extracellular vesicles by antihyperglycemic therapies: A pilot randomized controlled trial.
Baldassarre MPA · Journal of diabetes and its complications · 2026
Randomized controlled trial · 5 results
- Effects of liraglutide treatment for 18 days on metabolic parameters, regional body composition and the myostatin-activin-follistatin-IGF-1 axis: Results from an exploratory, randomized, placebo-controlled, crossover study.
Gutierrez de Piñeres V · Diabetes, obesity & metabolism · 2026
Randomized controlled trial · 9 results
- The Effect of Glycemic Control on Renal Triglyceride Content Assessed by Proton Spectroscopy in Patients With Type 2 Diabetes Mellitus: A Single-Center Parallel-Group Trial.
Dekkers IA · Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation · 2021
Randomized controlled trial · 1 result
- Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial.
Buse JB · Diabetes care · 2020
Randomized controlled trial · 3 results
- Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial.
Anholm C · Atherosclerosis · 2019
Randomized controlled trial · 7 results
- Change in HbA1c Across the Baseline HbA1c Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents.
Gentilella R · Diabetes therapy : research, treatment and education of diabetes and related disorders · 2019
Randomized controlled trial · 9 results
- The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial.
Dhatariya K · Diabetes care · 2018
Randomized controlled trial · 5 results
- Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience.
Zinman B · Diabetes care · 2018
Randomized controlled trial · 2 results
- Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial.
Steinberg WM · Diabetes care · 2017
Randomized controlled trial · 6 results
- Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial.
Verma S · JAMA cardiology · 2019
Randomized controlled trial · 4 results
- Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial.
Nauck MA · Diabetes care · 2019
Randomized controlled trial · 4 results
- Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease.
Mann JFE · Clinical journal of the American Society of Nephrology : CJASN · 2020
Randomized controlled trial · 4 results
- The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials.
Leiter LA · Diabetes, obesity & metabolism · 2020
Randomized controlled trial · 4 results
- Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial.
Mosenzon O · Diabetes, obesity & metabolism · 2020
Randomized controlled trial · 2 results
- Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials.
Verma S · Diabetes, obesity & metabolism · 2020
Randomized controlled trial · 4 results
- Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial.
Tack CJ · Diabetes, obesity & metabolism · 2019
Randomized controlled trial · 6 results
- Efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the SCALE and phase II randomized trials.
Ard J · Diabetes, obesity & metabolism · 2016
Randomized controlled trial · 7 results
- Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study).
Green JB · Circulation · 2024
Randomized controlled trial · 6 results
- Association of Baseline Factors With Glycemic Outcomes in GRADE: A Comparative Effectiveness Randomized Clinical Trial.
Garvey WT · Diabetes care · 2024
Randomized controlled trial · 2 results
- Comparative Effects of Randomized Second-line Therapy for Type 2 Diabetes on a Composite Outcome Incorporating Glycemic Control, Body Weight, and Hypoglycemia: An Analysis of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
Kirkman MS · Diabetes care · 2024
Randomized controlled trial · 8 results
- Glycemia reduction in type 2 diabetes-Hypoglycemia outcomes: A randomized clinical trial.
Seaquist ER · PloS one · 2024
Randomized controlled trial · 2 results
- Differences in Prevalence and Incidence of Electrocardiogram Abnormalities and Cardiovascular Autonomic Neuropathy Among Randomized Glucose-Lowering Treatments in Early Type 2 Diabetes: The Glycemia Reduction Approaches in Diabetes (GRADE) Cohort.
Pop-Busui R · Diabetes care · 2025
Randomized controlled trial · 4 results
- EFFECTS OF LIRAGLUTIDE 3.0 MG ON WEIGHT AND RISK FACTORS IN HISPANIC VERSUS NON-HIPANIC POPULATIONS: SUBGROUP ANALYSIS FROM SCALE RANDOMIZED TRIALS.
O'Neil PM · Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2016
Randomized controlled trial · 8 results
- Exposure-response analyses of liraglutide 3.0 mg for weight management.
Wilding JP · Diabetes, obesity & metabolism · 2016
Randomized controlled trial · 5 results
- Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials.
von Scholten BJ · Journal of diabetes and its complications · 2017
Randomized controlled trial · 5 results
- Improvements in health-related quality of life with liraglutide 3.0 mg compared with placebo in weight management.
Kolotkin RL · Clinical obesity · 2016
Randomized controlled trial · 7 results
- Improvements in health-related quality of life over 3 years with liraglutide 3.0 mg compared with placebo in participants with overweight or obesity.
Kolotkin RL · Clinical obesity · 2018
Randomized controlled trial · 5 results
- Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
Nauck M · Diabetes care · 2009
Randomized controlled trial · 8 results
- Comparison of the Continuous Glucose Monitoring Profiles of Four Glucose-Lowering Medications in the GRADE Randomized Trial.
Bergenstal RM · Diabetes care · 2026
Randomized controlled trial · 8 results
- Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes.
D'Alessio D · Diabetes, obesity & metabolism · 2015
Randomized controlled trial · 7 results
- Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial(*).
Yang W · Diabetes, obesity & metabolism · 2011
Randomized controlled trial · 11 results
- Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: Incidence and consequences.
Horowitz M · Diabetes, obesity & metabolism · 2017
Randomized controlled trial · 7 results
- Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial.
Ahrén B · Diabetes care · 2016
Randomized controlled trial · 10 results
- Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials.
Buse JB · The Journal of clinical endocrinology and metabolism · 2011
Randomized controlled trial · 6 results
- Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults.
Lean ME · International journal of obesity (2005) · 2014
Randomized controlled trial · 9 results
- Liraglutide and Recurrent Stroke by Baseline Insulin Resistance: A Post Hoc Analysis of the LAMP Trial.
Lu L · Stroke · 2026
Randomized controlled trial · 6 results
- Efficacy and safety of liraglutide, a once-daily human glucagon-like peptide-1 analogue, in Latino/Hispanic patients with type 2 diabetes: post hoc analysis of data from four phase III trials.
Davidson JA · Diabetes, obesity & metabolism · 2016
Randomized controlled trial · 6 results
- Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes.
Seino Y · Current medical research and opinion · 2010
Randomized controlled trial · 8 results
- Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes.
Rodbard HW · Diabetes, obesity & metabolism · 2016
Randomized controlled trial · 9 results
- Patient-reported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label study.
Schmidt WE · Diabetic medicine : a journal of the British Diabetic Association · 2011
Randomized controlled trial · 18 results
- Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis.
Overgaard RV · Clinical pharmacokinetics · 2016
Randomized controlled trial · 9 results
- Efficacy and Safety of Dapagliflozin versus Liraglutide in Patients with Overweight or Obesity and Type 2 Diabetes Mellitus: A Randomised Controlled Clinical Trial in Tianjin, China.
Zhaohu H · Journal of diabetes research · 2022
Randomized controlled trial · 6 results
- Efficacy of liraglutide added to sodium-glucose cotransporter-2 inhibitors in type 2 diabetes, stratified by baseline characteristics: Post-hoc analysis of LIRA-ADD2SGLT2i.
Blonde L · Diabetes, obesity & metabolism · 2021
Randomized controlled trial · 10 results
- Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial.
Wadden TA · Obesity (Silver Spring, Md.) · 2020
Randomized controlled trial · 5 results
- Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial.
Davies MJ · Diabetes care · 2016
Randomized controlled trial · 7 results
- Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction: Insights From the FIGHT Trial.
Redouane B · Circulation. Heart failure · 2020
Randomized controlled trial · 2 results
- Plasma metabolites associated with functional and clinical outcomes in heart failure with reduced ejection fraction with and without type 2 diabetes.
Lerman JB · Scientific reports · 2022
Randomized controlled trial · 1 result